Clinical trials: Cancer Disease Progression
Resectable Pancreatic Ductal Adenocarcinoma
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
This is a single arm, non-randomized phase II study of neoadjuvant metformin in resectable PDAC. Twenty patients will be enrolled and treated with metformin 500 mg BD for a minimum of 7 days, until 2 days prior to surgery.
- Trial name
- Metformin 001 (NCT02978547)
- Testing
- Metformin Hydrochloride 500Mg Tablet
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Glioma Glioblastoma Multiforme
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Subjects with histologically proven glioblastoma (GBM) who are suspected to have progression and are candidates for a surgical resection according to standard of care may be eligible for this study.
- Trial name
- Axumin (NCT03990285)
- Testing
- Axumin, Intravenous Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ali Nabavizadeh
Brain Tumor
Disease Progression and Treatment-induced Alterations in Glioblastoma
Summary of scientific evidence and rationale of this project: Integrative molecular-genetic approaches have provided important insights in the biology of glioblastoma.
- Trial name
- NCT02152748
- Testing
- analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Breast Neoplasms
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant…
- Trial name
- NCT02613026
- Testing
- Pirarubicin, Docetaxel, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 104 people
- Sponsor
- 307 Hospital of PLA
Myeloid Malignancies, Lymphoid Malignancies
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
This is a randomized, parallel phase II study to evaluate the rates of progression-free survival and unacceptable toxicity in patients receiving NK cell-enriched donor lymphocyte infusions (DLIs) when administered alone or…
- Trial name
- NK-DCI (NCT02452697)
- Testing
- NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cristina Gasparetto
Cachexia, Cancer
Effectiveness of Nutritional Counselling and "Improved Atta" Supplementation in Cachexic Adult Indian Cancer Patients
Investigators are evaluating the nutritional role of IAtta supplementation along with nutritional counselling in delaying the progression of cachexia to refractory cachexia in adult cancer Indian patients.
- Trial name
- NCT02561143
- Testing
- Improved Atta, Wheat flour, Physical activity counseling
- Where
- 2 sites in India, United Kingdom
- Volunteers
- 150 people
- Sponsor
- University of Westminster
Recurrent Endometrial Cancer
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a…
- Trial name
- NCT07594015
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Miami
Cervical Cancer, Metastatic Cancer
The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery
The purpose of this study is to investigate the efficacy of intravenous lidocaine on THBS2, MMPs and VEGF-C in serum in cervical cancer patients undergoing radical hysterectomy under general anesthesia.
- Trial name
- NCT05560035
- Testing
- Lidocaine, Normal saline (NS)
- Volunteers
- 60 people
- Sponsor
- General Hospital of Ningxia Medical University
PSA Level Greater Than 0.03, PSA Progression
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery.
- Conditions
- PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03541850
- Testing
- Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rectal Neoplasms
Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET
The purpose of this study is to investigate if PET/CT and MRI scans performed early in treatment and six weeks after treatment can predict the response of rectal cancer following chemotherapy and radiotherapy.
- Trial name
- PRISM (NCT02233374)
- Testing
- Early MRI and PET/CT - 2 weeks after commencing chemo/RT, Late MRI and PET/CT 6 weeks post chemo/RT
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- Royal North Shore Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- NCT03516617
- Testing
- Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Mayo Clinic
Barrett Esophagus, Esophageal Cancer
Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma
This study will examine the hypothesis that altered esophageal microbiome leads to the development of esophageal adenocarcinoma (EAC).
- Trial name
- NCT03216135
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ochsner Health System
Gastrointestinal Cancer
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.
- Trial name
- NCT00089960
- Testing
- AMG 706
- Volunteers
- 138 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Trial name
- NCT07100080
- Testing
- Iza-bren, Carboplatin, Cisplatin
- Where
- 187 sites in United States, Argentina and 23 more
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous…
- Trial name
- NCT07024173
- Testing
- HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Iadademstat + SBRT With Atezo in ES-SCLC
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor…
- Trial name
- TIARA (NCT07113691)
- Testing
- Iadademstat, Atezolizumab, SBRT
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Brain Malignancies, Pseudoprogression
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).
- Trial name
- NCT06199479
- Testing
- MRI Scan, CT Scan, Biopsy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
IPMN, Pancreatic
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Intraductal papillary mucinous neoplasms (IPMN) are one of the main precursor lesions of pancreatic ductal adenocarcinoma (PDAC), a lethal disease predicted to become the second leading cause of cancer-related deaths in Western…
- Trial name
- NCT06574373
- Testing
- Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention
- Where
- 2 sites in Italy
- Volunteers
- 3,600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Triple Negative Breast Cancer
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery.
- Trial name
- NCT07066189
- Testing
- Exercise and Medical Nutrition
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Yale University
Prostate Cancer
TherApeutics in Early ProState Cancer (TAPS02)
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate…
- Trial name
- NCT05191680
- Testing
- Apalutamide Oral Tablet [Erleada]
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.